BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Lenvatinib: trial readouts and FDA decisions

5 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 8 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: AstraZeneca, 3D Medicines (Sichuan) Co., Ltd., Merck Sharp & Dohme LLC, Akeso, Lion TCR Pte. Ltd., Mirror Biologics, Inc., AbbVie, Hoffmann-La Roche. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P2AkesoNCT06984718 A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCCHCC; Hepatocellular Carcinomanot yet recruiting120
2026-11-30 est.P2AstraZeneca AZNNCT07081633 Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaHepatocellular Carcinomaactive not recruiting114
2026-12 est.P1/P23D Medicines (Sichuan) Co., Ltd.NCT05024214 Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsSolid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinomarecruiting170
2026-12 est.P23D Medicines (Sichuan) Co., Ltd.NCT05112991 Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial CancerAdvanced Endometrial Cancerrecruiting108
2026-12 est.P2Lion TCR Pte. Ltd.NCT05195294 Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCCHepatocellular Carcinoma; Liver Cancer, Adult; Liver Cell Carcinomanot yet recruiting55

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-01 est.P2/P3Mirror Biologics, Inc.NCT05033522 Immunotherapy for Advanced Liver CancerHepatocellular Carcinomasuspended150
2026-11 est.P2AbbVie ABBVNCT05822752 Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab Hepatocellular Carcinomaactive not recruiting130
2026-10-27 est.P2AstraZeneca AZNNCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerHepatocellular Carcinoma; Biliary Tract Canceractive not recruiting294
2026-10-14 est.P3Hoffmann-La RocheNCT04770896 A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BUnresectable Hepatocellular Carcinomaactive not recruiting557
2026-08-10P1/P2Merck Sharp & Dohme LLC MRKNCT04626479 Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)Carcinoma, Renal Cellcompleted393
2026-07-23P1/P2Merck Sharp & Dohme LLC MRKNCT04626518 Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)Carcinoma, Renal Cellcompleted263
2026-07-09P3Bristol-Myers Squibb BMYNCT04039607 A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaHepatocellular Carcinomacompleted732
2026-05-23P3BeOne Medicines ONCNCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesAdvanced Malignanciescompleted404

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.